araag2/HINT huggingface dataset:
Clinical trial NCT00129948 (phase 2, status: terminated)
Conditions: leukemia, myeloid, acute
ICD codes: C92.A1, C92.A2, C92.61, C92.62, C92.A0, C92.60
Drugs: troxatyl™ (troxacitabine)
SMILES: [H][C@]1(CO)OC[C@]([H])(O1)N1C=CC(=N)N=C1O
Eligibility criteria:

        Inclusion Criteria:

          -  Confirmed diagnosis of acute myeloid leukemia (AML) in the second salvage setting:
             refractory to two prior courses of therapy or primary refractory without response to
             two previous courses of leukemia therapy.

          -  Patients must have received at least two previous courses of induction chemotherapy to
             be considered in the second salvage setting.

          -  Patients who are in second relapse, must have had a duration of their second CR or CRp
             of less than six months.

          -  Subjects must have adequate organ and immune function as indicated by the following
             laboratory values:

               -  Creatinine clearance ≥ 45 mL/min and ≤ 125 mL/min;

               -  Total bilirubin ≤ 2.0 mg/dL (≤ 34.2 µmol/L);

               -  AST (SGOT) and ALT (SGPT) ≤ 3 x upper limit of normal (ULN).

               -  Subjects must have an Eastern Cooperative Oncology Group (ECOG) performance
                  status of < 2, and an estimated life expectancy of at least eight weeks.

        Exclusion Criteria:

          -  Clinical evidence of active central nervous system (CNS) leukemic involvement

          -  Active and uncontrolled infection

          -  Uncontrolled medical problems unrelated to the malignancy that impair patient ability
             to give informed consent or unacceptably reduce the safety of the proposed treatment

          -  Neurologic or psychiatric disorders that would interfere with informed consent or
             study follow-up

          -  Known or suspected intolerance or hypersensitivity to Troxatyl® or closely related
             compounds such as lamivudine or any of the stated ingredients

          -  A recent history of alcohol or other substance abuse

          -  Subjects who have used another investigational agent or participated in a clinical
             trial within the last 14 days prior to enrolment

          -  Females with a positive pregnancy test at screening

          -  Subjects who have previously been enrolled into this study and subsequently withdrew
Clinical trial NCT00003786 (phase 2, status: withdrawn)
Conditions: colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: irofulven
SMILES: CC1=C(CO)C2=C(C)C3(CC3)[C@@](C)(O)C(=O)C2=C1
Reason stopped: 
    no participants
  
Eligibility criteria:

        DISEASE CHARACTERISTICS: Histologically confirmed metastatic or locally recurrent
        adenocarcinoma of the colon or rectum Bidimensionally measurable disease Lesions seen on
        colonoscopic examination or barium studies, bone metastases, CNS lesions, CEA levels and
        ascites are not considered measurable No CNS disease only CNS metastases with other sites
        of measurable disease allowed provided appropriate therapy for CNS metastases has been
        administered and patient is neurologically stable and does not require intravenous steroid
        or anticonvulsant therapy

        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 OR Zubrod 0-2 Life
        expectancy: At least 12 weeks Hematopoietic: WBC at least 3,500/mm3 Absolute neutrophil
        count at least 1,500/mm3 Platelet count at least 100,000/mm3 (no platelet transfusion
        within 7 days) Hemoglobin at least 9.0 g/dL Hepatic: Bilirubin no greater than 1.5 mg/dL
        Transaminases no greater than 2.5 times upper limit of normal Renal: Creatinine no greater
        than 1.5 mg/dL OR Creatinine clearance at least 60 mL/min Other: Not pregnant or nursing
        Negative pregnancy test Fertile patients must use effective contraception No significant
        uncontrolled medical or psychiatric illness No serious active infection No other active
        malignancy except nonmelanoma skin cancer or carcinoma in situ of the cervix unless
        adequately treated and less than 30% risk of relapse

        PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent prophylactic use of growth
        factors except for documented febrile neutropenia or sepsis Chemotherapy: At least 12
        months since prior fluorouracil based adjuvant or neoadjuvant chemotherapy No more than 1
        prior regimen No prior chemotherapy for advanced metastatic colorectal cancer No other
        concurrent chemotherapy No concurrent investigational antineoplastic drugs Endocrine
        therapy: See Disease Characteristics Radiotherapy: At least 4 weeks since prior
        radiotherapy and recovered No prior radiotherapy to the only site of measurable disease No
        concurrent radiotherapy Surgery: Not specified Other: See Disease Characteristics At least
        30 days since prior investigational drug
Clinical trial NCT00200382 (phase 2, status: terminated)
Conditions: non-small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: ps-341 (velcade-drug)
SMILES: CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O
Reason stopped: 
    the study did not achieve the statistical success to continue.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patients must have confirmed NSCLC (squamous, adeno- and large cell anaplastic
             carcinoma)stage III B or Stage IV.

        No prior chemotherapy regimen Patients must have adequate organ and marrow function

        Exclusion Criteria:

          -  Untreated symptomatic brain metastasis Patients with known HIV positivity
Clinical trial NCT00189566 (phase 2, status: completed)
Conditions: ovarian cancer, fallopian tube cancer, malignant tumor of peritoneum
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, C57.00, C57.01, C57.02, C48.2, C48.1, C78.6, C48.8
Drugs: paclitaxel, topotecan, carboplatin
SMILES: [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(C=CC(O)=C4CN(C)C)N=C13)C2=O, N[C@@H](CCCNC(N)=N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients aged > 18

          -  Histologically proven diagnosis of cancer of the ovary, the fallopian tube or
             peritoneum

          -  Peritoneal and/or nodes and/or visceral metastases

          -  Disease in progression under treatment or within 6 months after a first or second
             platinum-based line

          -  A period of 3 weeks between last chemotherapy and inclusion

          -  Measurable disease (Response Evaluation Criteria in Solid Tumors [RECIST] criteria) or
             cancer antigen (CA) 125 assessable disease (Gynecologic Cancer Intergroup [GCIG]
             criteria)

          -  ECOG performance status < 2

          -  Life expectancy of at least 12 weeks

        Exclusion Criteria:

          -  Previously received weekly administration of paclitaxel chemotherapy

          -  Involved in a trial within the last 30 days

          -  Previously received a bone marrow autogreffe or irradiation of the abdomen within 5
             years, due to intensive chemotherapy

          -  Prior diagnosis of malignancy

          -  History of ischemic cardiopathy, congestive heart failure (New York Heart Association
             [NYHA] > 2), arrhythmia, hypertension, or significant valvulopathy

          -  Pre-existing motor or sensory neurologic pathology or symptoms National Cancer
             Institute (NCI) - Common Terminology Criteria for Adverse Events (CTCAE) grade > 2

          -  Bone marrow, renal, or hepatic insufficiency

          -  Severe active infection or occlusive or sub-occlusive disease

          -  History of symptomatic brain metastases

          -  Fertile women not using adequate contraceptive methods

          -  Pregnant or breast feeding women

          -  Hypersensitivity to compounds chemically related to paclitaxel, topotecan, or
             carboplatin
Clinical trial NCT00556075 (phase 2, status: terminated)
Conditions: endometriosis
ICD codes: N80.8, N80.9, N80.0, N80.1, N80.5, N80.2, N80.3
Drugs: proellex 25 mg, placebo, proellex 50 mg
SMILES: [H][C@@]12CC[C@](OC(C)=O)(C(=O)COC)[C@@]1(C)C[C@H](C1=CC=C(C=C1)N(C)C)C1=C3CCC(=O)C=C3CC[C@@]21[H], CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]12CC[C@](OC(C)=O)(C(=O)COC)[C@@]1(C)C[C@H](C1=CC=C(C=C1)N(C)C)C1=C3CCC(=O)C=C3CC[C@@]21[H]
Reason stopped: 
    clinical hold for safety
  
Eligibility criteria:

        Inclusion Criteria:

          -  Premenopausal women aged 18-48 inclusive

          -  Endometriosis documented by laparoscopic or surgical assessment within the past ten
             (10) years

          -  Clinical symptoms of endometriosis for at least the past three (3) months

          -  Endometriosis symptoms

          -  Must be sexually active unless sexually inactive for endometriosis-related dyspareunia

          -  Must have a regular or steady menstrual cycle lasting from 24 to 36 days and a
             detectable ovulation during the baseline period using an ovulation monitoring kit (for
             timing of endometrial biopsy)

          -  Other inclusion criteria may apply

        Exclusion Criteria:

          -  Six (6) months or more without a menstrual period, or

          -  Prior hysterectomy or

          -  Prior bilateral oophorectomy

          -  Diagnosis of osteopenia

          -  Present history or condition that causes non-endometriosis-related dyspareunia

          -  Presence of excessive bleeding or menorrhagia

          -  Abnormal screening endometrial biopsy

          -  Other exclusion criteria may apply
Clinical trial NCT01225549 (phase 2, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: azd5423, budesonide 200 microgram, placebo, placebo
SMILES: COC1=CC(=CC=C1)[C@@H](OC1=CC=C2N(N=CC2=C1)C1=CC=C(F)C=C1)[C@H](C)NC(=O)C(F)(F)F, [H][C@@]12C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  18-60 years of age

          -  Pre-bronchodilatory FEV1 ≥70% of predicted normal allergic asthmatic with a history of
             episodic wheeze

          -  Positive allergen induced early and late airway bronchoconstriction showing ≥ 20% fall
             in FEV1 for the early and ≥ 15% for the late response

          -  Positive skin prick test to common aeroallergens

        Exclusion Criteria:

          -  Any clinically significant disease or disorder

          -  Any clinically relevant abnormal finding at screening examinations

          -  Smoker or ex-smoker who has stopped smoking < 12 months prior to study start

          -  Worsening of asthma or respiratory infection within 6 weeks from visit 1

          -  Allergen-specific immunotherapy within 6 months prior to visit 1
Clinical trial NCT00089128 (phase 2, status: terminated)
Conditions: bladder cancer
ICD codes: D30.3, C67.5, C67.9, C79.11, C67.0, C67.1, D41.4
Drugs: gemcitabine hydrochloride, irinotecan hydrochloride
SMILES: NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F, CCC1=C2CN3C(=CC4=C(COC(=O)[C@]4(O)CC)C3=O)C2=NC2=CC=C(OC(=O)N3CCC(CC3)N3CCCCC3)C=C12
Reason stopped: 
    low accrual
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed transitional cell carcinoma of the bladder

               -  Locally advanced or metastatic disease

          -  Unidimensionally measurable disease by physical exam or imaging study

               -  The following are not considered measurable disease:

                    -  Bone only disease

                    -  Pleural or peritoneal effusions

                    -  CNS lesions

                    -  Irradiated lesions unless disease progression was documented after
                       radiotherapy

          -  Not amenable to surgery

        PATIENT CHARACTERISTICS:

        Age

          -  Over 18

        Performance status

          -  ECOG 0-2

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Granulocyte count ≥ 1,500/mm^3

          -  Platelet count ≥ 100,000/mm^3

        Hepatic

          -  Bilirubin ≤ 2.0 mg/dL

        Renal

          -  Creatinine ≤ 2.0 mg/dL

        Gastrointestinal

          -  No active inflammatory bowel disease

          -  No significant bowel obstruction

          -  No chronic diarrhea

        Other

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No other active malignancy except nonmelanoma skin cancer

          -  No mental incapacitation or psychiatric illness that would preclude giving informed
             consent

          -  No other severe disease that would preclude study participation

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  No concurrent prophylactic filgrastim (G-CSF) or sargramostim (GM-CSF)

        Chemotherapy

          -  No more than 1 prior platinum-based chemotherapy regimen

          -  At least 4 weeks since prior chemotherapy

          -  No prior irinotecan or gemcitabine

          -  No other concurrent chemotherapy

        Endocrine therapy

          -  No concurrent hormones except steroids for adrenal failure, hormones for
             non-disease-related conditions (e.g., insulin for diabetes), and intermittent
             dexamethasone as an antiemetic

        Radiotherapy

          -  See Disease Characteristics

          -  At least 4 weeks since prior radiotherapy

          -  No concurrent palliative radiotherapy

        Surgery

          -  Not specified

        Other

          -  No concurrent participation in another clinical trial
Clinical trial NCT00357357 (phase 2, status: completed)
Conditions: alzheimer's disease
ICD codes: G30.8, G30.9, G30.0, G30.1
Drugs: hf0220
SMILES: [H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@H](O)C[C@@]2([H])C[C@@H](O)CC[C@]12C
Eligibility criteria:

        RECRUITMENT OF PARTICIPANTS IS PERFORMED ONLY BY STUDY SITES

        INCLUSION CRITERIA:

        Participants must meet the following inclusion criteria to be eligible.

          -  Male or Female (age over 55 years). Females must be non-child-bearing potential. Male
             patients with female partners of child-bearing potential should use effective
             contraception for the duration of the Study.

          -  A diagnosis of probable Alzheimer's disease established in accordance with the
             National Institute of Neurological and Communicative Disorders and Stroke /Alzheimer's
             disease and Related Disorders Association (NINCDS-ADRDA) classification.

          -  Severity of dementia of mild to moderate as assessed by the Mini-Mental State
             Examination (MMSE) score of 12-24.

          -  Patients must be living in the community living with or have at least daily visits
             from a responsible carer. The carer should be capable of assisting with the patient's
             medication, and prepared to attend with the patient for assessment.

          -  Written consent should be obtained from the patient and responsible carer.

        EXCLUSION CRITERIA

        Patients will not be eligible to participate in the study if they meet any of the following
        criteria:

          -  Primary, secondary or pseudodementias other than probable Alzheimer's disease.

          -  Clinically significant and/or uncontrolled condition or other significant medical
             disease.

          -  If taking medication for symptoms of dementia, the patient must be stable on therapy
             and have been taking these for a minimum of 3 months prior to enrolment.

          -  Treatment within the previous 3 months with any drug known to have a well defined
             potential for hepatotoxicity.

          -  Non-steroidal or steroidal anti-inflammatory agents. However, patients stable on low
             dose aspirin (upto 300mg/day) for at least 3 month prior to enrolment will be
             eligible.

          -  Taking anti-oxidant supplements.

          -  Active smokers of tobacco.

          -  Considered to be malnourished (body mass index <19).

          -  Patients in whom a lumbar puncture is contra-indicated.
Clinical trial NCT00265863 (phase 2, status: terminated)
Conditions: metastatic cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: mitomycin c
SMILES: CO[C@]12[C@H]3N[C@H]3CN1C1=C([C@H]2COC(N)=O)C(=O)C(N)=C(C)C1=O
Reason stopped: 
    withdrawn due to slow accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of peritoneal metastases and malignant ascites by physical examination,
             ultrasound, or CT scan

          -  Not eligible for cytoreductive surgery based on any of the following criteria:

               -  Metastases outside peritoneal cavity

               -  Poor performance status

               -  Unresectable peritoneal disease

          -  Must have undergone at least 1 prior paracentesis procedure

          -  No ascites caused by any of the following conditions:

               -  Cardiac failure

               -  Nephrotic syndrome

               -  Pancreatic ascites

               -  Chylous ascites

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-3

          -  WBC ≥ 3,000/mm^3

          -  Platelet count ≥ 70,000/mm^3

          -  Bilirubin ≤ 2.0 mg/dL

          -  Creatinine ≤ 1.5 mg/dL

          -  Not pregnant or nursing

          -  Negative pregnancy test

        Exclusion Criteria:

          -  Prior peritoneal chemotherapy

          -  Dense intraabdominal adhesions limiting laparoscopy
Clinical trial NCT01482221 (phase 2, status: completed)
Conditions: major depressive disorder
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: azd6765 iv, azd6765 iv, placebo
SMILES: N[C@@H](CC1=CC=CC=N1)C1=CC=CC=C1, N[C@@H](CC1=CC=CC=N1)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Provision of signed and dated informed consent before initiation of any study-related
             procedures.

          -  Male or female patients aged 18 to 70 years, inclusive.

          -  The patient must have a clinical diagnosis of major depressive disorder with a
             lifetime history of inadequate response to at least 3 antidepressants.

          -  Women of child-bearing potential must have a negative serum pregnancy test and
             confirmed use of a highly effective form of birth control before enrollment for a
             minimum of 3 months before study start.

          -  Outpatient status at screening and randomization visits.

        Exclusion Criteria:

          -  Patients with a history of diagnosed bipolar disorder or schizophrenia or
             schizoaffective disorder or currently exhibiting psychotic features associated with
             their depression; dementia or suspicion thereof.

          -  Patients who have had a suicide attempt within the last 6 months.

          -  Electroconvulsive therapy (ECT), vagal nerve stimulation (VNS) or transcranial
             magnetic stimulation (TMS) or previous treatment with ketamine infusion within the 6
             months prior to screening, or any history of deep brain stimulation.

          -  Patients with any history of seizure disorder (except for febrile seizures in
             childhood).

          -  Pregnancy or lactation.
Clinical trial NCT00022633 (phase 2, status: terminated)
Conditions: bladder cancer, transitional cell cancer of the renal pelvis and ureter, urethral cancer
ICD codes: D30.3, C67.5, C67.9, C79.11, C67.0, C67.1, D41.4
Drugs: gemcitabine hydrochloride, paclitaxel
SMILES: NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC
Reason stopped: 
    permanently closed due to poor accrual
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed urothelial cancer

               -  Transitional cell carcinoma, adenocarcinoma, or squamous carcinoma (bladder,
                  renal pelvis, ureter, or urethra)

          -  Previously untreated metastatic or locoregionally advanced (i.e., bulky pelvic nodes)
             disease OR

          -  Locally recurrent carcinoma after radiotherapy or cystectomy and no longer eligible
             for further radiotherapy or surgery

          -  Measurable disease

        PATIENT CHARACTERISTICS:

        Age:

          -  70 and over OR

          -  Under 60

        Performance status:

          -  Zubrod 0-2

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Absolute granulocyte count at least 1,200/mm^3

          -  Platelet count at least 100,000/mm^3

        Hepatic:

          -  Bilirubin no greater than upper limit of normal (ULN)

          -  Aspartate aminotransferase (SGOT) or alanine aminotransferase (SGPT) no greater than 2
             times ULN

        Renal:

          -  Creatinine no greater than ULN

        Other:

          -  HIV negative

          -  No other concurrent life-threatening medical disorder that would preclude study
             participation

          -  No other prior malignancy within the past 5 years except adequately treated basal cell
             or squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated
             stage I or II cancer in complete remission

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  Prior adjuvant chemotherapy is allowed provided administered more than 10 years ago

          -  No prior gemcitabine, taxanes, or platinum-based adjuvant chemotherapy

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  See Disease Characteristics

          -  At least 28 days since prior radiotherapy and recovered

        Surgery:

          -  See Disease Characteristics

          -  At least 28 days since prior surgery and recovered